Close
Contact

Manufacturing challenges and considerations for Allogeneic Cell Therapy

The allogeneic cell therapy (ACT) space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.

To better elucidate these challenges we spoke to 15 key opinion leaders within the ACT space. We summarized their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.

This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.

To download your copy of the full report, please submit the details using the form on the right.  A copy of the report will automatically download after submission.

Do you have a future market research project that you’d like to discuss with us?

Contact
  • Allogeneic cell therapy

Customer Care

Inside Intelligence

Address: 52 Grosvenor Gardens, London, SW1W 0AU.
Tel: +44 (0)20 3141 8700

Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.

Enabling growth is at the heart of what we do.

© Hanson Wade 2024. Hanson Wade Limited is registered in England & Wales, number 06752216. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.